IVR tests are part of the pharmaceutical industry, aimed to quantify drug release kinetics during pharmaceutical development. Current IVR methodologies are resource intensive processes and consist of laborious, time-consuming and repetitive tasks. In addition, in vivo studies are needed to establish a correlation with the IVR tests.
As the price of drug development continues to soar, there is great need for new approaches that can improve upon the predictive quality and operational efficiency of in vitro testing. We are developing an innovative model for IVR testing systems with microfluidics technology.
Our technology enables the creation of fully automated and miniaturised IVR testing systems which not only optimize resource management, but also enable massive parallelization for tests with significant economies of scale. Furthermore, the precise control of experimental conditions and the very low volumes involved in microfluidics solutions match the requirements of 2D and 3D cell cultures as well as organs on a chip, which is key to narrowing the bridge between in vitro and in vivo environments.
The goal of this new generation of cost-effective, biologically relevant IVR testing systems is to reduce in vivo testing and accelerate the pre-clinical drug development process.